EVE · ASX

EVE Health Group Limited (ASX:EVE)

AU$0.032

 -0.002 (-5.882%)
ASX:Live
20/06/2025 01:29:50 PM
HALO Ords GROWTH AUS Big Candle All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

EVE Overview

EVE Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About EVE

Website

N/A

Telephone

61.8.6465.5500

Address

Suite 1 245 Churchill Avenue Subiaco, Western Australia (WA) 6008

Description

EVE Health Group Ltd. engages in the development and provision of health and wellness solutions. Its portfolio includes Omni Innovation, Meluka Australia, Jenbrook Australia, and Naturally Australian Products. It operates through the following segments: Jenbrook, Meluka, and Investment. The company was founded on October 1, 2003 and is headquartered in Subiaco, Australia.

EVE Price Chart

Key Stats

Market Cap

AU$8.34M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.02 - 0.04

Trade Value (12mth)

AU$617.00

1 week

-2.86%

1 month

-15%

YTD

-15%

1 year

-15%

All time high

8.52

Key Fundamentals

EPS 3 yr Growth

-54.60%

EBITDA Margin

-72.00%

Operating Cashflow

-$1m

Free Cash Flow Return

-50.90%

ROIC

-71.20%

Interest Coverage

-44.00

Quick Ratio

1.80

Other Data

Shares on Issue (Fully Dilluted)

132m

HALO Sector

Healthcare

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

EVE Announcements

Latest Announcements

Date Announcements

17 June 25

Change of Director's Interest Notice

×

Change of Director's Interest Notice

16 June 25

Prescribing Agreement for ED and Dysmenorrhea Products

×

Prescribing Agreement for ED and Dysmenorrhea Products

13 June 25

EVE Investor Webinar

×

EVE Investor Webinar

12 June 25

Application for quotation of securities - EVE

×

Application for quotation of securities - EVE

12 June 25

EVE Completes Nextract Acquisition

×

EVE Completes Nextract Acquisition

12 June 25

Final Director's Interest Notice

×

Final Director's Interest Notice

12 June 25

Initial Director's Interest Notice

×

Initial Director's Interest Notice

12 June 25

Becoming a substantial holder

×

Becoming a substantial holder

12 June 25

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

11 June 25

Completion of Share Consolidation

×

Completion of Share Consolidation

11 June 25

Change of Director's Interest Notice x 2

×

Change of Director's Interest Notice x 2

11 June 25

Prospectus

×

Prospectus

02 June 25

Stability Testing Starts for ED and Dysmenorrhoea Products

×

Stability Testing Starts for ED and Dysmenorrhoea Products

29 May 25

Trading Halt

×

Trading Halt

29 May 25

GM Presentation

×

GM Presentation

29 May 25

Results of Meeting

×

Results of Meeting

30 April 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

29 April 25

Notice of General Meeting/Proxy Form

×

Notice of General Meeting/Proxy Form

29 April 25

Letter to Shareholders - General Meeting

×

Letter to Shareholders - General Meeting

29 April 25

Update - Proposed issue of securities - EVE

×

Update - Proposed issue of securities - EVE

29 April 25

Consolidation/Split - EVE

×

Consolidation/Split - EVE

29 April 25

Update - Proposed issue of securities - EVE

×

Update - Proposed issue of securities - EVE

14 April 25

EVE to Acquire Nextract, Expanding into $5.3B ED Market

×

EVE to Acquire Nextract, Expanding into $5.3B ED Market

14 April 25

Proposed issue of securities - EVE

×

Proposed issue of securities - EVE

14 April 25

Proposed issue of securities - EVE

×

Proposed issue of securities - EVE

14 April 25

Investor Presentation - Nextract Acquisition

×

Investor Presentation - Nextract Acquisition

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

EVE Shortsell

Frequently Asked Questions

The current share price of EVE Health Group Limited (EVE:ASX) is AU$0.032.
The 52-week high share price for EVE Health Group Limited (EVE:ASX) is AU$0.04.
The 52-week low share price for EVE Health Group Limited (EVE:ASX)? is AU$0.02.
EVE Health Group Limited (EVE:ASX) does not pay a dividend.
EVE Health Group Limited (EVE:ASX) does not pay a dividend.
EVE Health Group Limited (EVE:ASX) has a franking level of 0.0%.
EVE Health Group Limited (EVE:ASX) is classified in the Healthcare.
The current P/E ratio for EVE Health Group Limited (EVE:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.